{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:59:07Z","timestamp":1793642347412,"version":"4.5.1"},"reference-count":64,"publisher":"American Academy of Pediatrics (AAP)","issue":"Supplement_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND:<\/jats:title>\n                  <jats:p>Autism spectrum disorder (ASD) is increasingly recognized as a public health issue. Irritability and aggression (IA) often negatively affect the lives of people with ASD and their families. Although many medications have been tested for IA in ASDs in randomized controlled trials (RCTs), critical quantitative analyses of these trials are lacking in the literature.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>OBJECTIVES:<\/jats:title>\n                  <jats:p>To systematically review and quantitatively analyze the efficacy and safety of pharmacologic treatments for IA in youth with ASD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>DATA SOURCES:<\/jats:title>\n                  <jats:p>Studies were identified from Medline, PsycINFO, Embase, and review articles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>Original articles on placebo-controlled RCTs of pharmacologic treatments of IA in youth age 2 to 17 years with ASD were included. Data items included study design, study goals, details of study participants, details of intervention, study results, statistical methods, side effects, and risks of bias. The primary study outcome measure was the effect size of reduction in the Aberrant Behavioral Checklist\u2013Irritability (ABC-I) scores in the medication group, as compared with placebo, in RCTs using parallel groups design.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>Forty-six RCTs were identified. Compared with placebo, 3 compounds resulted in significant improvement in ABC-I at the end of treatment. Risperidone and aripiprazole were found to be the most effective, with the largest effect sizes. Sedation, extrapyramidal sides effects, and weight gain were assessed quantitatively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>Although risperidone and aripiprazole have the strongest evidence in reducing ABC-I in youth with ASD, a few other compounds also showed significant efficacy with fewer potential side effects and adverse reactions in single studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2015-2851k","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T09:42:43Z","timestamp":1454319763000},"page":"S124-S135","source":"Crossref","is-referenced-by-count":221,"title":["Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis"],"prefix":"10.1542","volume":"137","author":[{"given":"Lawrence K.","family":"Fung","sequence":"first","affiliation":[{"name":"Department of Psychiatry & Behavioral Sciences, Stanford University, Stanford, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneesh","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute and Johns Hopkins University School of Medicine, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alixandra","family":"Nozzolillo","sequence":"additional","affiliation":[{"name":"Center for Child & Adolescent Health Research and Policy, MassGeneral Hospital for Children, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Bernal","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California, San Jose, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Krasner","sequence":"additional","affiliation":[{"name":"New York\u2013Presbyterian Hospital\/Columbia University Medical Center, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Booil","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry & Behavioral Sciences, Stanford University, Stanford, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Coury","sequence":"additional","affiliation":[{"name":"Department of Developmental & Behavioral Pediatrics, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Whitaker","sequence":"additional","affiliation":[{"name":"New York\u2013Presbyterian Hospital\/Columbia University Medical Center, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Veenstra-Vanderweele","sequence":"additional","affiliation":[{"name":"New York\u2013Presbyterian Hospital\/Columbia University Medical Center, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Y.","family":"Hardan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry & Behavioral Sciences, Stanford University, Stanford, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"issue":"2","key":"2021120906210118000_B1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1192\/bjp.147.2.127","article-title":"Irritability: definition, assessment and associated factors","volume":"147","author":"Snaith","year":"1985","journal-title":"Br J Psychiatry"},{"key":"2021120906210118000_B2","volume-title":"Irritability","author":"Vorvick","year":"2009"},{"issue":"2","key":"2021120906210118000_B3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1467-8624.2004.00674.x","article-title":"Emotion-related regulation: sharpening the definition.","volume":"75","author":"Eisenberg","year":"2004","journal-title":"Child Dev"},{"issue":"4","key":"2021120906210118000_B4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1176\/appi.ajp.2008.07111774","article-title":"Neurobiology of aggression and violence.","volume":"165","author":"Siever","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"5479","key":"2021120906210118000_B5","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1126\/science.289.5479.591","article-title":"Dysfunction in the neural circuitry of emotion regulation: a possible prelude to violence.","volume":"289","author":"Davidson","year":"2000","journal-title":"Science"},{"issue":"5","key":"2021120906210118000_B6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.biopsych.2013.08.036","article-title":"The development of the neural substrates of cognitive control in adolescents with autism spectrum disorders.","volume":"76","author":"Solomon","year":"2013","journal-title":"Biol Psychiatry"},{"issue":"7","key":"2021120906210118000_B7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hbm.21085","article-title":"Altered intrinsic functional connectivity of anterior and posterior insula regions in high-functioning participants with autism spectrum disorder.","volume":"32","author":"Ebisch","year":"2011","journal-title":"Hum Brain Mapp"},{"issue":"4","key":"2021120906210118000_B8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/aur.88","article-title":"Decreased GABAA receptors and benzodiazepine binding sites in the anterior cingulate cortex in autism.","volume":"2","author":"Oblak","year":"2009","journal-title":"Autism Res"},{"key":"2021120906210118000_B9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuropharm.2012.04.008","article-title":"The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study.","volume":"68","author":"Mendez","year":"2013","journal-title":"Neuropharmacology"},{"issue":"8","key":"2021120906210118000_B10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s10803-006-0147-5","article-title":"Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification.","volume":"36","author":"Lecavalier","year":"2006","journal-title":"J Autism Dev Disord"},{"issue":"7","key":"2021120906210118000_B11","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s10803-013-2022-5","article-title":"Emotion dysregulation and the core features of autism spectrum disorder.","volume":"44","author":"Samson","year":"2014","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"2021120906210118000_B12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems.","volume":"347","author":"McCracken","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"2021120906210118000_B13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","article-title":"Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial.","volume":"37","author":"Pandina","year":"2007","journal-title":"J Autism Dev Disord"},{"key":"2021120906210118000_B14","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2021120906210118000_B15","author":"AHRQ","year":"2008"},{"issue":"7650","key":"2021120906210118000_B16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"2021120906210118000_B17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence.","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7414","key":"2021120906210118000_B18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"5","key":"2021120906210118000_B19","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"issue":"3","key":"2021120906210118000_B20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10803-006-0078-1","article-title":"A crossover study of risperidone in children, adolescents and adults with mental retardation.","volume":"36","author":"Hellings","year":"2006","journal-title":"J Autism Dev Disord"},{"issue":"8","key":"2021120906210118000_B21","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10803-012-1723-5","article-title":"Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study.","volume":"43","author":"Kent","year":"2013","journal-title":"J Autism Dev Disord"},{"issue":"6","key":"2021120906210118000_B22","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"issue":"11","key":"2021120906210118000_B23","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.","volume":"48","author":"Marcus","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"2021120906210118000_B24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/cap.2005.15.682","article-title":"A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders.","volume":"15","author":"Hellings","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"2021120906210118000_B25","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/npp.2009.202","article-title":"Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders.","volume":"35","author":"Hollander","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"2021120906210118000_B26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF02179289","article-title":"Use of methylphenidate in the treatment of children with autistic disorder.","volume":"25","author":"Quintana","year":"1995","journal-title":"J Autism Dev Disord"},{"issue":"3","key":"2021120906210118000_B27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1005548619694","article-title":"Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.","volume":"30","author":"Handen","year":"2000","journal-title":"J Autism Dev Disord"},{"issue":"10","key":"2021120906210118000_B28","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","article-title":"Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.","volume":"45","author":"Arnold","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"2021120906210118000_B29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archgenpsychiatry.2009.30","article-title":"Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.","volume":"66","author":"King","year":"2009","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"2021120906210118000_B30","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199210000-00005","article-title":"Clonidine treatment of hyperactive and impulsive children with autistic disorder.","volume":"12","author":"Jaselskis","year":"1992","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"2021120906210118000_B31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1362361307070989","article-title":"A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism.","volume":"11","author":"Woodard","year":"2007","journal-title":"Autism"},{"issue":"6","key":"2021120906210118000_B32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.yic.0000224787.13782.0f","article-title":"Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.","volume":"21","author":"Wasserman","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"2021120906210118000_B33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/cap.2011.0056","article-title":"Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders.","volume":"22","author":"Arnold","year":"2012","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"2021120906210118000_B34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0165-1781(95)02749-M","article-title":"Placebo-controlled acute dosage naltrexone study in young autistic children.","volume":"58","author":"Willemsen-Swinkels","year":"1995","journal-title":"Psychiatry Res"},{"issue":"12","key":"2021120906210118000_B35","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0006-3223(95)00297-9","article-title":"The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.","volume":"39","author":"Willemsen-Swinkels","year":"1996","journal-title":"Biol Psychiatry"},{"issue":"4","key":"2021120906210118000_B36","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.biopsych.2006.05.007","article-title":"Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study.","volume":"61","author":"Amminger","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"11","key":"2021120906210118000_B37","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/00004583-200111000-00009","article-title":"Multisite, double-blind, placebo-controlled trial of porcine secretin in autism.","volume":"40","author":"Owley","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"2021120906210118000_B38","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hup.491","article-title":"Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder.","volume":"18","author":"Niederhofer","year":"2003","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"2021120906210118000_B39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2217\/14750708.1.1.87","article-title":"Venlafaxine has modest effects in autistic children.","volume":"1","author":"Niederhofer","year":"2004","journal-title":"Therapy"},{"issue":"6","key":"2021120906210118000_B40","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/00004583-200106000-00010","article-title":"Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.","volume":"40","author":"King","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"2021120906210118000_B41","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.biopsych.2012.01.014","article-title":"A randomized controlled pilot trial of oral N-acetylcysteine in children with autism.","volume":"71","author":"Hardan","year":"2012","journal-title":"Biol Psychiatry"},{"issue":"6","key":"2021120906210118000_B42","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/08830738060210060801","article-title":"Risperidone in children with autism: randomized, placebo-controlled, double-blind study.","volume":"21","author":"Nagaraj","year":"2006","journal-title":"J Child Neurol"},{"issue":"4","key":"2021120906210118000_B43","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0002-7138(09)61017-7","article-title":"A comparison of haloperidol and behavior therapy and their interaction in autistic children.","volume":"17","author":"Campbell","year":"1978","journal-title":"J Am Acad Child Psychiatry"},{"issue":"10","key":"2021120906210118000_B44","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/ajp.141.10.1195","article-title":"Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms.","volume":"141","author":"Anderson","year":"1984","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2021120906210118000_B45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00787-007-0620-5","article-title":"Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial.","volume":"17","author":"Miral","year":"2008","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"6","key":"2021120906210118000_B46","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.1993.01820180039004","article-title":"A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder.","volume":"50","author":"Gordon","year":"1993","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"2021120906210118000_B47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0165-1781(95)02601-R","article-title":"Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study.","volume":"58","author":"Bouvard","year":"1995","journal-title":"Psychiatry Res"},{"key":"2021120906210118000_B48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1471-2431-11-111","article-title":"Effect of a vitamin\/mineral supplement on children and adults with autism.","volume":"11","author":"Adams","year":"2011","journal-title":"BMC Pediatr"},{"issue":"4","key":"2021120906210118000_B49","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1023\/A:1025861522935","article-title":"High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study.","volume":"27","author":"Findling","year":"1997","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"2021120906210118000_B50","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.jcp.0000177667.35016.e9","article-title":"Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study.","volume":"25","author":"Danfors","year":"2005","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"2021120906210118000_B51","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.","volume":"162","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"11","key":"2021120906210118000_B52","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","article-title":"Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.","volume":"44","author":"Troost","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"2021120906210118000_B53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/JCP.13m08500","article-title":"A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder.","volume":"75","author":"Findling","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"2021120906210118000_B54","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/cap.2006.16.575","article-title":"Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy.","volume":"16","author":"Luby","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"16","key":"2021120906210118000_B55","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"issue":"9","key":"2021120906210118000_B56","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4088\/JCP.09m05933","article-title":"Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.","volume":"72","author":"Marcus","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"2021120906210118000_B57","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/cap.2013.0099","article-title":"Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole.","volume":"24","author":"Wink","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"10","key":"2021120906210118000_B58","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamapsychiatry.2013.2053","article-title":"Antipsychotics and the risk of type 2 diabetes mellitus in children and youth.","volume":"70","author":"Bobo","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"2021120906210118000_B59","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamapsychiatry.2013.4030","article-title":"Diabetes risk potentially underestimated in youth and children receiving antipsychotics.","volume":"71","author":"Samaras","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"2021120906210118000_B60","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00004714-200108000-00012","article-title":"Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study.","volume":"21","author":"Remington","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"2021120906210118000_B61","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/cap.2009.0120","article-title":"Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder.","volume":"20","author":"Aman","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"2021120906210118000_B62","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaac.2011.11.010","article-title":"Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems.","volume":"51","author":"Scahill","year":"2012","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"2021120906210118000_B63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/cap.2009.0048","article-title":"Effectiveness of medication combined with intensive behavioral intervention for reducing aggression in youth with autism spectrum disorder.","volume":"20","author":"Frazier","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"12","key":"2021120906210118000_B64","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/CHI.0b013e3181bfd669","article-title":"Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.","volume":"48","author":"Aman","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/137\/Supplement_2\/S124\/884430\/peds_20152851k.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/137\/Supplement_2\/S124\/884430\/peds_20152851k.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:43:07Z","timestamp":1639096987000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/137\/Supplement_2\/S124\/34019\/Pharmacologic-Treatment-of-Severe-Irritability-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":64,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2016,2,1]]},"published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2015-2851k","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,1]]}}}